ArticleThe American journal of tropical medicine and hygiene2026
Identification of Mycobacterium leprae and Mycobacterium lepromatosis Cases with Broad-Range Molecular Assays at a Single Large Reference Laboratory.
Article in The American journal of tropical medicine and hygiene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Definitively diagnosing Hansen's disease (HD) is challenging, but molecular methods can provide species identification of the causative mycobacteria (Mycobacterium leprae and Mycobacterium lepromatosis). Most studies have investigated targeted assays, and the performance of broad-range molecular approaches remains unknown. This study evaluated a multilocus (hsp65, 16S ribosomal RNA, and rpoB) broad-range polymerase chain reaction (PCR) assay in detecting HD-associated mycobacteria at a single large reference laboratory in the United States from 2009 to 2024. We identified 148 positive samples from 137 patients submitted from 26 states. Mycobacterium lepromatosis was identified in 8 of 137 patients (5.8%), and M. leprae was identified in the rest. Although most samples were skin biopsies (∼90%), 10 samples (7.9%) represented atypical locations, including bone marrow and liver. Half of all samples were identified by only a single target (n = 72/146 samples, 49.3%), and rpoB was the most likely to be positive (n = 123/146 samples, 84.2%). Overall, broad-range PCR successfully identified HD-associated mycobacteria, including M. lepromatosis, from skin and atypical anatomic sites, and it should be considered more frequently in the evaluation of suspected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.